Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL M DAO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1437321932
CMS profile
337948
Location
GARDEN GROVE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$6,263.60

258 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $6,203.05 256
Education $60.55 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $580.55 16
Novo Nordisk Inc $538.01 22
ABBVIE INC. $427.90 21
Amgen Inc. $387.24 17
Boehringer Ingelheim Pharmaceuticals, Inc. $303.35 11
Bayer HealthCare Pharmaceuticals Inc. $288.34 14
Gilead Sciences, Inc. $287.71 11
Horizon Therapeutics plc $278.60 12
Nestle HealthCare Nutrition Inc. $219.45 6
Novartis Pharmaceuticals Corporation $214.72 19
Lilly USA, LLC $202.53 7
Janssen Pharmaceuticals, Inc $193.78 5
Mylan Specialty L.P. $192.08 7
Esperion Therapeutics, Inc. $181.34 4
UCB, Inc. $153.70 9
Sun Pharmaceutical Industries Inc. $151.76 5
Biohaven Pharmaceutical Holding Company Ltd. $125.08 6
GENZYME CORPORATION $120.54 1
Salix Pharmaceuticals, a division of Bausch Health US, LLC $119.44 10
IMPEL PHARMACEUTICALS INC. $114.99 1
SANOFI-AVENTIS U.S. LLC $97.79 4
ITI, Inc. $90.01 3
Amarin Pharma Inc. $88.00 5
Intuitive Surgical, Inc. $86.75 1
Merck Sharp & Dohme LLC $85.81 5
Ironwood Pharmaceuticals, Inc $82.34 4
Boston Scientific Corporation $69.26 1
Regeneron Healthcare Solutions, Inc. $54.81 2
Antares Pharma, Inc. $51.68 3
PFIZER INC. $45.43 2
Almatica Pharma LLC $45.29 3
Allergan, Inc. $43.90 2
Kowa Pharmaceuticals America, Inc. $39.30 3
Astellas Pharma US Inc $27.24 2
CeQur Corporation $25.56 1
Corium, LLC $23.71 1
LEO Pharma Inc. $22.53 1
GlaxoSmithKline, LLC. $22.50 1
Avanir Pharmaceuticals, Inc. $21.20 1
Oyster Point Pharma, Inc. $21.18 1
VBI Vaccines (Delaware) Inc. $19.80 1
Dynavax Technologies Corporation $18.76 1
VIVUS LLC $18.51 1
Takeda Pharmaceuticals U.S.A., Inc. $18.36 1
Galderma Laboratories, L.P. $16.95 1
Paratek Pharmaceuticals, Inc. $15.59 1
INTRA-SANA LABORATORIES $15.21 1
Acerus Pharmaceuticals Corporation $15.02 1

Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL M DAO

NPI 1437321932 · CMS profile ID 337948

Allopathic & Osteopathic Physicians / Internal Medicine

GARDEN GROVE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437321932?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL M DAO, NPI 1437321932, CMS profile ID 337948. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437321932?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MICHAEL M DAO, NPI 1437321932, CMS profile ID 337948. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437321932?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MICHAEL M DAO, NPI 1437321932, CMS profile ID 337948, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1437321932?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

258 matching records · $6,263.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 258 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 258.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $11.7106/10/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918198623 CMS
Amgen Inc. $10.5006/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939950177 CMS
Novartis Pharmaceuticals Corporation $3.6706/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893591619 CMS
Novartis Pharmaceuticals Corporation $5.5406/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893591621 CMS
Novo Nordisk Inc $24.6906/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898600071 CMS
ABBVIE INC. $23.8406/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890828149 CMS
Amarin Pharma Inc. $16.9406/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913957591 CMS
Amgen Inc. $122.3106/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939471479 CMS
Nestle HealthCare Nutrition Inc. $21.3706/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902773415 CMS
Horizon Therapeutics plc $8.1405/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937610825 CMS
Horizon Therapeutics plc $13.8205/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937610823 CMS
Gilead Sciences, Inc. $6.6305/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929497505 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.7205/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929977117 CMS
Horizon Therapeutics plc $121.6305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937610821 CMS
Novartis Pharmaceuticals Corporation $14.5005/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893591617 CMS
Novo Nordisk Inc $24.1705/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898600065 CMS
Merck Sharp & Dohme LLC $11.7105/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944176949 CMS
Regeneron Healthcare Solutions, Inc. $18.8005/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927143295 CMS
Novo Nordisk Inc $120.8905/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898864047 CMS
AstraZeneca Pharmaceuticals LP $12.5005/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915780053 CMS
Biohaven Pharmaceutical Holding Company Ltd. $18.5705/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923569747 CMS
Ironwood Pharmaceuticals, Inc $20.9705/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957925381 CMS
ABBVIE INC. $13.1005/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890828147 CMS
Horizon Therapeutics plc $17.7805/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937610819 CMS
Amarin Pharma Inc. $17.7605/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913959031 CMS
Amgen Inc. $18.5705/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939471467 CMS
Lilly USA, LLC $22.6305/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918268445 CMS
Mylan Specialty L.P. $3.0804/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963905205 CMS
AstraZeneca Pharmaceuticals LP $128.7504/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915258565 CMS
Janssen Pharmaceuticals, Inc $122.7104/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885759353 CMS
Novartis Pharmaceuticals Corporation $21.3204/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893591615 CMS
Bayer HealthCare Pharmaceuticals Inc. $11.5304/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929879553 CMS
ABBVIE INC. $14.4504/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890828145 CMS
Regeneron Healthcare Solutions, Inc. $36.0104/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927143291 CMS
Gilead Sciences, Inc. $28.2304/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929497529 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $124.4904/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887711121 CMS
UCB, Inc. $19.9004/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907985147 CMS
Esperion Therapeutics, Inc. $21.4004/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947250437 CMS
AstraZeneca Pharmaceuticals LP $17.1004/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915820167 CMS
Amgen Inc. $30.1404/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939950175 CMS
Mylan Specialty L.P. $13.0604/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963902823 CMS
Kowa Pharmaceuticals America, Inc. $14.4604/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900331795 CMS
ABBVIE INC. $14.9104/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890828143 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.3504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887711233 CMS
Biohaven Pharmaceutical Holding Company Ltd. $20.0504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923569745 CMS
Nestle HealthCare Nutrition Inc. $115.9504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902773413 CMS
Gilead Sciences, Inc. $20.6604/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929497521 CMS
Lilly USA, LLC $19.9604/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918203791 CMS
ABBVIE INC. $5.6304/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890828141 CMS
Novartis Pharmaceuticals Corporation $16.6403/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893591613 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,431.84 316
PY2020 $7,527.22 245
PY2021 $6,862.27 337
PY2022 $6,263.60 258
PY2023 $6,441.40 281
PY2024 $7,580.36 302
PY2025 $10,507.47 306

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $550,613.82 26
PY2024 Principal investigator $344,392.32 269
PY2023 Principal investigator $842,190.10 383
PY2022 Principal investigator $391,336.90 273
PY2021 Principal investigator $231,496.56 57
PY2020 Principal investigator $6,000.00 3
PY2019 Principal investigator $55,715.00 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,477.14 12/19/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520600
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,711.35 12/17/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 12/10/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520604
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,766.00 11/11/2025 Non-covered Recipient Entity
National Institute Of Clinical Research, Inc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225415310
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,250.00 10/31/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185543644
Principal investigator 1 Alnylam Pharmaceuticals Inc. $758.41 10/24/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520612
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,064.50 08/27/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520534
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,400.00 08/06/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia No dispute reported 06/30/2026 1185543640
Principal investigator 1 AstraZeneca Pharmaceuticals LP $349,547.00 07/31/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185543642
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,206.58 07/16/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $53,106.60 07/14/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215520538
Principal investigator 1 Alnylam Pharmaceuticals Inc. $211.00 07/14/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215520542
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $5,689.72 06/25/2025 Non-covered Recipient Entity
National Institute Of Clinical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235995507
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,366.00 05/29/2025 Non-covered Recipient Entity
National Institute Of Clinical Research, Inc
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225412690
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,481.26 04/18/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520527
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,850.00 04/16/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185543648
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,387.00 04/01/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520522
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $10,000.00 03/18/2025 Non-covered Recipient Entity
National Institute Of Clinical Research, Inc
BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney No dispute reported 06/30/2026 1225405276
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 03/12/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520490
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,538.30 03/12/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520494
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 02/21/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520484
Principal investigator 1 Alnylam Pharmaceuticals Inc. $426.42 02/21/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 02/21/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520508
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,483.14 02/03/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520498
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,645.28 02/03/2025 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520504
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,248.12 01/29/2025 Non-covered Recipient Entity
NATIONAL INSTITUTE OF CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185543646